Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Plows $354m Into Phlow

Start-Up Is Awarded Contract To Manufacture Essential Medicines In US

Executive Summary

US start-up Phlow has been awarded federal government funding of $354m as part of a contract to manufacture essential medicines in the US amid the COVID-19 pandemic, in partnership with AMPAC Fine Chemicals and Civica Rx.

You may also be interested in...

‘Patience Young Grasshopper’: Former Phlow Exec Admits Securities Fraud Over US Kodak Loan

Kodak’s surprise announcement in July 2020 that it was looking to secure a massive government loan to set up a pharma division at the height of the COVID-19 pandemic was leaked by an executive at Phlow, which was assisting the firm, to his cousin, allowing both men to realize hundreds of thousands of dollars in illicit profits from fraudulent share trading.

Environmental Regulations May Create Barriers To Onshoring More Rx Manufacturing

The House Ways and Means Committee may take more of a kitchen sink approach to addressing drug shortages than other congressional committees that have been primarily focused on paying for quality. Hearing witnesses said Congress must follow through on funding incentives for US onshoring. 

Civica Rx COO McCoy To Step Into CEO Role From 1 June

Civica Rx’s chief operating officer Ned McCoy is to step up as CEO, ahead of the company’s landmark manufacturing facility commencing operations in early 2024.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts